Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California. more
Time Frame | ILMN | Sector | S&P500 |
---|---|---|---|
1-Week Return | 5.75% | 1.89% | -0.81% |
1-Month Return | -7.16% | -2.71% | -3.95% |
3-Month Return | -11.57% | 1.31% | 3.35% |
6-Month Return | 4.18% | 11.93% | 19.7% |
1-Year Return | -45.67% | 6.35% | 22.93% |
3-Year Return | -70.01% | 19.71% | 25.5% |
5-Year Return | -61.36% | 76.38% | 85.41% |
10-Year Return | -19.02% | 186.71% | 221.1% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 3.54B | 3.24B | 4.53B | 4.58B | 4.50B | [{"date":"2019-12-31","value":77.29,"profit":true},{"date":"2020-12-31","value":70.66,"profit":true},{"date":"2021-12-31","value":98.73,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.25,"profit":true}] |
Cost of Revenue | 1.08B | 1.04B | 1.37B | 1.61B | 1.76B | [{"date":"2019-12-31","value":61.14,"profit":true},{"date":"2020-12-31","value":58.86,"profit":true},{"date":"2021-12-31","value":77.95,"profit":true},{"date":"2022-12-31","value":91.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 2.47B | 2.20B | 3.15B | 2.97B | 2.74B | [{"date":"2019-12-31","value":78.22,"profit":true},{"date":"2020-12-31","value":69.85,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":94.23,"profit":true},{"date":"2023-12-31","value":87,"profit":true}] |
Gross Margin | 69.63% | 68.01% | 69.69% | 64.83% | 60.92% | [{"date":"2019-12-31","value":99.92,"profit":true},{"date":"2020-12-31","value":97.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.04,"profit":true},{"date":"2023-12-31","value":87.43,"profit":true}] |
Operating Expenses | 1.48B | 1.62B | 3.28B | 7.15B | 2.97B | [{"date":"2019-12-31","value":20.72,"profit":true},{"date":"2020-12-31","value":22.7,"profit":true},{"date":"2021-12-31","value":45.83,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.48,"profit":true}] |
Operating Income | 985.00M | 393.00M | (123.00M) | (4.18B) | (1.07B) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":39.9,"profit":true},{"date":"2021-12-31","value":-12.49,"profit":false},{"date":"2022-12-31","value":-424.26,"profit":false},{"date":"2023-12-31","value":-108.53,"profit":false}] |
Total Non-Operating Income/Expense | 156.00M | 455.00M | 946.00M | (8.84B) | (67.00M) | [{"date":"2019-12-31","value":16.49,"profit":true},{"date":"2020-12-31","value":48.1,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-934.88,"profit":false},{"date":"2023-12-31","value":-7.08,"profit":false}] |
Pre-Tax Income | 1.12B | 856.00M | 884.00M | (4.34B) | (1.12B) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":76.57,"profit":true},{"date":"2021-12-31","value":79.07,"profit":true},{"date":"2022-12-31","value":-387.84,"profit":false},{"date":"2023-12-31","value":-99.91,"profit":false}] |
Income Taxes | 128.00M | 200.00M | 122.00M | 68.00M | 44.00M | [{"date":"2019-12-31","value":64,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":61,"profit":true},{"date":"2022-12-31","value":34,"profit":true},{"date":"2023-12-31","value":22,"profit":true}] |
Income After Taxes | 990.00M | 656.00M | 762.00M | (4.40B) | (1.16B) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":66.26,"profit":true},{"date":"2021-12-31","value":76.97,"profit":true},{"date":"2022-12-31","value":-444.85,"profit":false},{"date":"2023-12-31","value":-117.27,"profit":false}] |
Income From Continuous Operations | 990.00M | 656.00M | 762.00M | (4.40B) | (1.16B) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":66.26,"profit":true},{"date":"2021-12-31","value":76.97,"profit":true},{"date":"2022-12-31","value":-444.85,"profit":false},{"date":"2023-12-31","value":-117.27,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 1.00B | 656.00M | 762.00M | (4.40B) | (1.16B) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":65.47,"profit":true},{"date":"2021-12-31","value":76.05,"profit":true},{"date":"2022-12-31","value":-439.52,"profit":false},{"date":"2023-12-31","value":-115.87,"profit":false}] |
EPS (Diluted) | 6.58 | 4.50 | 5.96 | 2.12 | 0.87 | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":68.39,"profit":true},{"date":"2021-12-31","value":90.58,"profit":true},{"date":"2022-12-31","value":32.22,"profit":true},{"date":"2023-12-31","value":13.22,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
ILMN | |
---|---|
Cash Ratio | 0.67 |
Current Ratio | 1.66 |
Quick Ratio | 1.29 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ILMN | |
---|---|
ROA (LTM) | -0.53% |
ROE (LTM) | -18.81% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ILMN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.43 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.57 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 1.76 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ILMN | |
---|---|
Trailing PE | NM |
Forward PE | 129.87 |
P/S (TTM) | 4.49 |
P/B | 3.52 |
Price/FCF | 111 |
EV/R | 4.76 |
EV/Ebitda | NM |
PEG | NM |
What kind of opportunities can an engineer find through their work? Plenty, at Illumina! One employee shares how she makes a difference.Originally published on Illumina News Center NORTHAMPTON, MA …
The Medical Genome Initiative presents a paper in an effort to expand patient access to sequencingOriginally published on Illumina News CenterNORTHAMPTON, MA / ACCESSWIRE / April 17, 2024 / A recen…
DNA Test Kits Market is estimated to be valued at USD 1.86 Bn in 2024 and is expected to reach USD 5.40 Bn by 2031, exhibiting a CAGR of 16.5% from 2024 to 2031 BURLINGAME, CALIFORNIA, UNITED STATES, April 15, 2024 /EINPresswire.com/ -- DNA Test …
The European Commission, exercising its authority under the EU Merger Regulation (EUMR), has granted approval to Illumina’s proposed divestment of GRAIL. This decision, crucial for the restoration of competitive equilibrium in the blood-based early cancer detection market, follows the Commission’s previous order in October 2023 requiring Illumina to reverse its acquisition of GRAIL. The deal […]
By Foo Yun Chee BRUSSELS (Reuters) -U.S. gene sequencing company Illumina (NASDAQ:)’s plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but […] The post EU approves Illumina’s plan to divest cancer test maker Grail By Reuters appeared first on TheAdviserMagazine.com .
SAN DIEGO (dpa-AFX) - Friday, Illumina, Inc. (ILMN) announced that its divestment plan for Grail has received approval from the European Commission. The method of divestment has not been finalized…
Illumina (ILMN) has issued an announcement. Illumina, Inc. has received the green light from the European Commission to move forward with its dives…
SAN DIEGO, April 12, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC). While this does not mean the method of…
Illumina Inc (ILMN) share price today is $124.46
Yes, Indians can buy shares of Illumina Inc (ILMN) on Vested. To buy Illumina Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ILMN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Illumina Inc (ILMN) via the Vested app. You can start investing in Illumina Inc (ILMN) with a minimum investment of $1.
You can invest in shares of Illumina Inc (ILMN) via Vested in three simple steps:
The 52-week high price of Illumina Inc (ILMN) is $217.6. The 52-week low price of Illumina Inc (ILMN) is $89.
The price-to-earnings (P/E) ratio of Illumina Inc (ILMN) is NM
The price-to-book (P/B) ratio of Illumina Inc (ILMN) is 3.52
The dividend yield of Illumina Inc (ILMN) is 0.00%
The market capitalization of Illumina Inc (ILMN) is $19.82B
The stock symbol (or ticker) of Illumina Inc is ILMN